Overview
Clinical Frame
A beta agonist can make breathing easier by widening narrowed airways, but bronchodilation is not the same as control of the disease causing the narrowing.
A beta-agonist can make breathing easier by widening narrowed airways, but bronchodilation is not the same as control of the disease causing the narrowing. In asthma, beta-agonists relieve bronchial smooth-muscle constriction; they do not treat the underlying airway inflammation. That distinction explains why frequent reliever use should prompt a review of anti-inflammatory controller therapy rather than repeated refills alone. Short-acting beta-agonists, or SABAs, are rapid bronchodilators used for acute symptoms. Long-acting beta-agonists, or LABAs, maintain bronchodilation for many hours. In asthma, a LABA must be paired with an inhaled corticosteroid (ICS); single-agent LABA treatment increases asthma-related risk. In chronic obstructive pulmonary disease (COPD), bronchodilator selection follows a different treatment framework, with long-acting dual bronchodilation preferred for many patients. Canadian practice uses the name salbutamol; albuterol is the same drug name used in US sources. The distinction between formoterol and salmeterol matters clinically: formoterol begins working quickly enough for use in specified ICS-formoterol reliever regimens, whereas salmeterol must never be used for acute symptom relief.